Bao Wanying, He Xinlin, Huang Yue, Liu Rongyu, Li Zhengyu
Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Key Laboratory of Birth Defects and Related Diseases of Women and Children, Department of Obstetrics and Gynecology, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, China.
Vaccines (Basel). 2024 Aug 23;12(9):956. doi: 10.3390/vaccines12090956.
The human papillomavirus (HPV) vaccine was initially approved for a three-dose regimen. Due to resource limitations, budget constraints, low acceptance, and poor adherence, global vaccination coverage is only 15%. A single-dose regimen could simplify logistics, reduce costs, and improve accessibility. However, its clinical effectiveness remains debatable. This review systematically searched PubMed, Embase, and Cochrane Library, including 42 clinical studies, to assess the effectiveness of a single-dose HPV vaccination for preventing HPV infections, cervical abnormalities, and genital warts. We summarized the effectiveness of bivalent, quadrivalent, and nonavalent vaccines across different age groups and buffer periods, and analyzed the factors contributing to the inconsistency of results. The review also provides insights into designing robust future research to inform single-dose HPV vaccination policies and guidelines, highlighting the need for further research to refine vaccination strategies.
人乳头瘤病毒（HPV）疫苗最初获批采用三剂接种方案。由于资源有限、预算紧张、接受度低以及依从性差，全球疫苗接种覆盖率仅为15%。单剂接种方案可以简化物流、降低成本并提高可及性。然而，其临床有效性仍存在争议。本综述系统检索了PubMed、Embase和Cochrane图书馆，纳入42项临床研究，以评估单剂HPV疫苗预防HPV感染、宫颈病变和尖锐湿疣的有效性。我们总结了二价、四价和九价疫苗在不同年龄组和缓冲期的有效性，并分析了导致结果不一致的因素。该综述还为设计强有力的未来研究提供了见解，以为单剂HPV疫苗接种政策和指南提供依据，强调需要进一步研究以完善疫苗接种策略。
